EchoGo® Heart Failure vs EchoNext
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 75/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Both tools leverage AI for cardiac disease detection and are FDA-cleared, making them comparable in their general aim to support cardiology. However, EchoGo® Heart Failure specifically analyzes echocardiograms for HFpEF detection, while EchoNext analyzes ECGs to screen for a broader range of hidden structural heart diseases, including heart failure, valve disease, and pulmonary hypertension. Therefore, the choice depends on whether the primary need is detailed echocardiogram analysis for HFpEF or a broader ECG-based screening for various structural heart conditions.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
EchoGo Heart Failure is designed for seamless integration, analyzing routine echo video clips and delivering automated structured reports via DICOM to PACS within 20 minutes. It can also integrate with HL7 messaging and offers an API for increased flexibility. EchoNext is available through the OpenEvidence clinical decision support platform, aiming to put its screening output in front of physicians using tools they already utilize at the point of care.
EchoGo Heart Failure has demonstrated high accuracy in detecting HFpEF, with a reported 90% sensitivity and 86% specificity. EchoNext, in retrospective analysis, detected composite structural heart disease with an AUROC of 85.2% and an AUPRC of 78.5%. In a comparison with cardiologists, EchoNext achieved 77% accuracy in detecting structural heart problems, while cardiologists alone achieved 64% and 69% with AI assistance.
EchoGo Heart Failure, analyzing echocardiograms, is specifically designed for the detection of Heart Failure with preserved Ejection Fraction (HFpEF), a condition often challenging to diagnose. EchoNext, which analyzes standard 12-lead ECGs, is suited for broad screening to detect hidden structural heart disease, including various forms of heart failure, valve disease, and pulmonary hypertension, identifying patients who may need further echocardiographic evaluation.
EchoGo Heart Failure is described as having no software installation or training required due to its SaaS model and seamless integration into existing echo workflows. While EchoNext's learning curve isn't explicitly detailed, its integration with the OpenEvidence platform suggests a focus on accessibility within familiar clinical decision support environments.
Ultromics offers dedicated support and customer success teams to provide guidance and insights for optimizing workflow with EchoGo Heart Failure. Pathway Labs, with EchoNext, emphasizes its dedication to delivering quality, accuracy, and exceptional customer service, and its partnership with OpenEvidence aims to provide broad access and support.
EchoGo Heart Failure is built on a robust and scalable cloud-native architecture, designed for easy integration with existing systems and capable of quick deployment at small practices or larger organizations. Ultromics has experience with real-world validation across multiple US medical sites. EchoNext is also designed for broad access, from major hospitals to community practices, and has shown robust performance across over 20 hospitals in the US and Canada.